You just read:

First Patients Dosed in Phase III Multi-center, Multinational Study to Determine the Efficacy, Safety and Tolerability of P2B001 in Patients with Early Stage Parkinson's Disease

News provided by

Pharma Two B Ltd

Feb 06, 2018, 09:00 EST